Access Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes propriety products for the treatment and supportive care of cancer patients. Its products include ProLindac, which is in Phase II clinical testing of patients with ovarian cancer; and MuGard for the management of patients with.. Read More

Acusphere, Inc., a specialty pharmaceutical company, develops new drugs and formulations of existing drugs using its proprietary porous microparticle technology in the United States. Its porous microparticle technology enables to control the size and porosity of particles, including nanoparticles and microparticles. The company develops products in the areas of cardiology, oncology, and asthma. Its lead product candidate Imagify, a cardiovascular drug is in Phase III clinical development for the detection of coronary artery disease. The companys products also include AI-850, a Phase I clinical trial completed product candidate that utilizes hydrophobic drug delivery system to improve the dissolution rate of a cancer drug; and AI-128, a Phase I clinical study completed formulation of asthma drug, which utilizes pulmonary drug delivery system. Acusphere has a license agreement with Cephalon, Inc. to provide license to Acuspheres Hydrophobic Drug Delivery System for oncology applications, along with the rights to AI-850, Acuspheres formulation of paclitaxel. The company was founded in 1993 and is headquartered in Tewksbury, Massachusetts.

Adolor Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of prescription pain management products. Its product includes ENTEREG (alvimopan), a small molecule peripherally-acting mu-opioid receptor antagonist designed to block the adverse side effects of opioid analgesics on the gastrointestinal tract, as well as for the management of postoperative ileus following bowel resection surgery that causes significant discomfort for patients. The companys product candidates in various stages of clinical and preclinical development include two novel delta opioid receptor agonists that are in mid-stage clinical development in collaboration with Pfizer Inc. for chronic pain; a mu opioid receptor antagonist entering development for chronic OBD; and various opioid and non-opioid discovery programs. Adolor Corporation was founded in 1993 and is headquartered in Exton, Pennsylvania.

Advanced Viral Research Corp., a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions in the United States. Its products include AVR118, a cytoprotective drug composed of a complex.. Read More

Aeolus Pharmaceuticals, Inc., a pharmaceutical company, engages in the development of medical countermeasures against biological, chemical, and radiological weapons in the United States. It also develops medical countermeasures for diseases and disorders of the central nervous system, respiratory system,.. Read More

Akesis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of Type 2 diabetes. Its products include AKP-020, a vanadium-based monotherapy that is in Phase IIa clinical trial for the treatment for Type 2 diabetes... Read More

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers. Alexion Pharmaceuticals drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors. Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut.

Alexza Pharmaceuticals, Inc., a specialty pharmaceutical development stage company, focuses on the research, development, and commercialization of products for the acute treatment of central nervous system conditions. Its technology, Staccato system, vaporizes an excipient-free drug to form a condensation aerosol that allows for systemic drug delivery. The company has six product candidates in clinical development, including AZ-004 (Staccato loxapine) that completed Phase 3 clinical trial for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-104 (Staccato loxapine), which completed Phase 2a clinical trial to treat patients suffering from acute migraine headaches; and AZ-001 (Staccato prochlorperazine) that completed Phase 2b clinical trials to treat patients suffering from acute migraine headaches. Its products in clinical development also include AZ-007 (Staccato zaleplon), which completed Phase 1 clinical trial for the treatment of insomnia in patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep; AZ-003 that completed Phase 1 clinical trial (Staccato fentanyl) for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes; and AZ-002 (Staccato alprazolam), which completed Phase 2a proof-of-concept clinical trial for the treatment of panic attacks. The company has a development agreement with Autoliv ASP, Inc. to develop heat packages to incorporate into the companys single dose drug delivery devices. It was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. The company was founded in 2000 and is based in Mountain View, California.

Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other.. Read More

Allos Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer. Its lead product candidate includes Pralatrexate, an antifolate under Phase II trial, which accumulates preferentially in cancer cells and treats patients with relapsed or refractory peripheral T-cell lymphoma. The company also offers RH1, a small molecule chemotherapeutic agent, which is under Phase I trial to treat patients with advanced solid tumors and non-Hodgkins lymphoma. In addition, it is evaluating Pralatrexate in various Phases for the treatment of non-Hodgkin's Lymphoma and Hodgkin's disease, cutaneous T-cell lymphoma, non-small cell lung cancer, bladder cancer, and other solid tumor indications. The company was formerly known as HemoTech Sciences, Inc. and changed its name to Allos Therapeutics, Inc. in October 1994. Allos Therapeutics, Inc. was founded in 1992 and is headquartered in Westminster, Colorado.

A pharmaceutical company, engaged in the research and development of innovative therapeutic products using advanced drug delivery technologies.

ALTANA Aktiengesellschaft engages in the development, manufacture, and marketing of chemical products for various applications worldwide. It provides special products for coatings manufacturers, coatings and plastics processors, and the electronics industry. The companys product range includes additives,.. Read More

Amarin Corporation plc operates as a biopharmaceutical company with a focus on cardiovascular diseases. Its cardiovascular programs focus in the field of lipid science and the known therapeutic benefits of essential fatty acids in cardiovascular disease. The companys lead product candidate includes AMR101, a prescription grade Omega-3 product comprising ultra-pure ethyl eicosapentaenoic acid, which is entering Phase III clinical trials for the treatment of hypertriglyceridemia and mixed dyslipidemia. Its pipeline also includes programs in the area of central nervous system disorders, including Huntingtons disease, myasthenia gravis, and Parkinsons disease. Amarin Corporation plc, formerly known as Ethical Holdings plc, was founded in 1989 and is based in Dublin, Ireland.

Amersin Life Sciences Corporation does not have significant operations. Previously, the company, through its subsidiary, Hubei Tongji Benda Ebei Pharmaceutical Co., Ltd., engaged in the manufacture and commercialization of pain management and generic pharmaceutical products in the Peoples Republic of China. The.. Read More

Angiotech Pharmaceuticals, Inc. provides technologies and medical products for local diseases and complications associated with medical device implants, surgical interventions, and acute injury in the United States and internationally. Its Pharmaceutical Technologies segment provides technologies that improve the.. Read More

Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), cancer, and inflammatory diseases in the United States. The companys lead product candidate includes RDEA594, a product for the treatment of hyperuricemia and gout. Its other products comprise RDEA806 for the treatment of patients with HIV; and RDEA427, a second-generation NNRTI for the treatment of HIV, in a human micro-dose pharmacokinetic study. Ardea Biosciences is evaluating RDEA119, a non-ATP EK inhibitor, in a Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. It also develops RDEA436 for the treatment of inflammation. The company is based in San Diego, California.

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases. The company also discovers small molecule drug candidates that target G protein-coupled receptors (GPCRs). Its clinical development programs include lorcaserin in Phase 3 trial program for the treatment of obesity; APD791, an anti-thrombotic drug candidate, which has completed Phase 1a and Phase 1b clinical trials; and APD125 that is in Phase 2b clinical trial for the treatment of insomnia. The companys clinical development programs also include APD597, an oral GPR119 agonist that is in Phase 1 clinical trial for the treatment of type 2 diabetes; APD916 drug candidate, which has completed preclinical development for the treatment of narcolepsy and cataplexy; and APD811, a preclinical drug candidate for the treatment of pulmonary arterial hypertension. Its drug candidates use GPCR-focused drug discovery and development approach, as well as technologies, including constitutively activated receptor technology and melanophore technology. The company has a collaboration agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. to further develop compounds for the potential treatment of type 2 diabetes and other disorders. Arena Pharmaceuticals, Inc. was founded in 1997 and is based in San Diego, California.

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets. Its lead product ARQ 197 is an orally administered inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in microphthalmia transcription factor associated tumors, non-small cell lung cancer, pancreatic adenocarcinoma, and hepatocellular carcinoma. The companys clinical stage products also include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. Its preclinical and discovery programs comprise ARQ 621 focused on inhibition of the Eg5 kinesin spindle protein; ARQ 761, a second-generation E2F-1 activator; and BRAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

ARYx Therapeutics, Inc., a biopharmaceutical company, focuses on developing a portfolio of product candidates designed to eliminate known safety issues associated with commercial drugs using its RetroMetabolic Drug Design technology. Its product portfolio includes tecarfarin, an oral anticoagulant in Phase II/III.. Read More

Astralis, Ltd. does not have significant operations. Previously, it was engaged in the research and development of treatments for immune system disorders and skin diseases, such as psoriasis, and psoriatic and rheumatoid arthritis. The company was founded in 1999 and is based in Fairfield, New Jersey.

AVANIR Pharmaceuticals, Inc. focuses on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders primarily in the United States and Canada. Its lead product candidate includes Zenviatm, which has completed three Phase III clinical trials for the.. Read More

AVI BioPharma, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products based on antisense and cancer immunotherapy technology. The companys products under various development stages comprise AVI-4658, a Phase I human clinical trial product to restore, prevent, or slow deterioration of muscle function; AVI-5038, a preclinical stage product to skip exon 50 and restore a range of associated mutations; AVI-5126, a Phase II clinical trial product for the treatment of cardiovascular restenosis; and AVI-6002 and AVI6003, which are in Phase I clinical trials to treat diseases caused by Dengue, Ebola, Marburg, and Junn viruses. It has strategic alliances with Chiron Corporation; Cook Group Incorporated; Ercole Biotech, Inc.; Eleos Inc.; Charleys Fund, Inc.; and the United States Department of Defense. The company was founded in 1980 and is based in Bothell, Washington.

Bayer AG offers pharmaceuticals and health care products, agricultural products, and polymers. It operates in three groups: HealthCare, CropScience, and MaterialScience. The HealthCare group engages in the development, production, and marketing of prescription pharmaceuticals, such as for the treatment of.. Read More

Biodel Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes. The company develops its product candidates by utilizing its proprietary VIAdel technology that allows to study the interaction between peptide hormones and small molecules. Its.. Read More

Bio-Warm Corporation, through its wholly owned subsidiary, Mirae Tech Company, Ltd., engages in the manufacture and marketing of far infrared conductive textile products in Japan, the Peoples Republic of China, and Europe. It produces plane heater heating mat, heating panel, heating wall paper, heating floor,.. Read More

Cardiome Pharma Corp., a life sciences company, focuses on developing drugs to treat or prevent cardiovascular diseases. Its product Vernakalant (iv), which has completed Phase III (ACT 4) and in Phase III (European Comparator) trial is used for the treatment of atrial fibrillation; Vernakalant (oral) that has.. Read More

Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products for central nervous system, inflammatory disease, pain, and oncology therapeutic areas. Its products for central nervous system disorders include PROVIGIL for the treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder; NUVIGIL, a single-isomer formulation of modafinil; and GABITRIL for use as an adjunctive therapy in the treatment of partial seizures in epileptic patients. The companys pain therapeutics portfolio comprises AMRIX for the relief of muscle spasm associated with acute painful musculoskeletal conditions; and FENTORA, EFFENTORA, ACTIQ, and generic OTFC products, which focus on treating breakthrough cancer pain in opioid-tolerant patients. Its products for oncology consist of TREANDA, a bi-functional hybrid cytotoxic; TRISENOX, an intravenous arsenic-based targeted therapy; CEP-701, an oral small molecule tyrosine kinase inhibitor; MYOCET, a cardio-protective chemotherapy agent to treat metastatic breast cancer; TARGRETIN for the treatment of cutaneous T-cell lymphoma; and ABELCET, an anti-fungal product for cancer patients. The company provides its products principally to wholesale drug distributors. It has collaboration agreements with Euroscreen s.a.; Ligand Pharmaceuticals Incorporated; Psychogenics Inc.; and AMBIT Biosciences Inc, as well as a research agreement with Celator Pharmaceuticals Inc. Cephalon, Inc. markets its products primarily in the United States, Europe, the Middle East, and Africa. The company was founded in 1987 and is headquartered in Frazer, Pennsylvania.

The Company is now a holding company whose business is carried out entirely by Shandong Spring Pharmaceutical Co., Ltd., which is engaged in distributing health and beauty aides as well as toiletries.

Cortex Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The company develops AMPAKINE compounds for the treatment of Alzheimers disease, mild cognitive impairment, attention deficit hyperactivity disorder, schizophrenia, depression, respiratory depression caused by opiate analgesics, and possibly sleep apnea. Its low impact AMPAKINE compounds include CX717 and CX1739, which are in phase II clinical development stage; and high impact compounds include CX929 for Huntingtons disease patients. The company has a research collaboration and exclusive worldwide license agreement with NV Organon to develop and commercialize its AMPAKINE technology for the treatment of schizophrenia and depression. Cortex Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

Cubist Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides in the United States. It began promoting MERREM I.V. (meropenem for injection) in the U.S. in July 2008. MERREM is an established spectrum antibiotic developed by AstraZeneca. The Cubist product pipeline includes ecallantide, a recombinant human protein in Phase 2 clinical trials; CONSERV-1 and CONSERV-2 for the reduction of blood loss during cardiac surgery; and two Phase 1 programs that address unmet medical needs, one in CDAD (Clostridium difficile-associated diarrhea) and the other in multi-drug resistant (MDR) Gram-negative infections. In addition, the company, in collaboration with Alnylam Pharmaceuticals, Inc., has a pre-IND and a Phase 2 program underway in novel treatments for respiratory syncytial virus infections using Alnylams RNA-interference technology. Cubist was founded in 1992 and is headquartered in Lexington, Massachusetts.

Carrington Laboratories, Inc. operates as a research-based biopharmaceutical, medical device, raw materials, and nutraceutical company. It engages in the development, manufacture, and marketing of naturally-derived complex carbohydrates and other natural product therapeutics for the treatment of major illnesses,.. Read More

Depomed, Inc., a specialty pharmaceutical company, develops and commercializes pharmaceutical products based on its proprietary oral drug delivery technologies in the United States. It markets GLUMETZA for the treatment of type 2 diabetes in the United States, Canada, and Korea; and Proquin XR for treatment of uncomplicated urinary tract infection in the United States. The companys under development products comprise DM-5689, a Phase III clinical trial product for the treatment of menopausal hot flashes; DM-1796, a Phase III clinical trial product for the treatment of postherpetic neuralgia, as well as is in Phase II clinical trail for diabetic peripheral neuropathy; DM-3458, a Phase I clinical trial product for the treatment of gastroesophageal reflux disease; and DM-1992, a Phase I clinical trial product that targets Parkinson's disease. It has collaboration and license agreements with PharmaNova, Inc.; Solvay Pharmaceuticals, Inc.; Supernus Pharmaceuticals, Inc.; Covidien Ltd.; Santarus, Inc.; Teva Pharmaceuticals USA, Inc.; Patheon, Inc.; Biovail Laboratories Incorporated; LG Life Sciences, Ltd.; Watson Pharmaceuticals, Inc.; and Rottapharm/Madaus S.r.l. The company sells its products to wholesalers and retail pharmacies. Depomed, Inc. was founded in 1995 and is based in Menlo Park, California.

DOV Pharmaceutical, Inc., a biopharmaceutical company, engages in the discovery, in-licensing, and development of novel drug candidates for central nervous system disorders. Its product candidate include DOV 21,947, a triple reuptake inhibitor, which is in Phase II clinical trials for depression, as well as in.. Read More

Dr. Reddys Laboratories Limited, together with its subsidiaries, operates as a pharmaceutical company. It produces finished dosage forms, active pharmaceutical ingredients and intermediates, and biotechnology products. The company also conducts research in the areas of cancer, diabetes, cardiovascular, inflammation, and bacterial infection. In addition, it involves in the contract manufacture generic prescription and over-the-counter products for branded and generic companies in the United States. The company primarily focuses on therapeutic categories of cardiovascular, diabetes management, gastro-intestinal, and pain management. It markets its products in India, the United States, Europe, and the Russian Federation. The company has a co-development and commercialization agreement with Rheoscience A/S for the development and commercialization of Balaglitazone/DRF 2593, a partial PPAR-gamma agonist for the treatment of type 2 diabetes; an agreement with ClinTec International for the development of an anti-cancer compound, DRF 1042; collaboration with the National Cancer Institute in Maryland; and an agreement with Argenta Discovery Limited for the joint development and commercialization of a novel approach to the treatment of chronic obstructive pulmonary disease. It also has an agreement with 7TM Pharma for drug discovery collaboration on selected drug targets; and an agreement with GlaxoSmithKline plc to develop and market pharmaceuticals for the treatment of cardiovascular disease, diabetes, oncology, gastroenterology, and pain management. Dr. Reddys Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.

DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceutical products for pain, central nervous system, disorders, cardiovascular disease, and other chronic diseases based on its proprietary drug formulations and delivery platform technologies. The companys products include POSIDUR, a release formulation of bupivacaine under Phase IIb clinical trial, which is used for the treatment of post-surgical pain; and ELADUR, a transdermal bupivacaine patch under Phase IIb clinical trial that provides continuous delivery of bupivacaine for up to three days from a single application, as well as is used for the treatment of pain associated with post-herpetic neuralgia. It also offers Remoxy, an oral oxycodone gelatin capsule under development with pain therapeutics; and TRANSDUR-Sufentanil, a proprietary transdermal sufentanil patch under development, which provides continuous delivery of sufentanil for a period of up to seven days from a single application. In addition, the company offers CHRONOGESIC (sufentanil), a pain therapy system; and ALZET, the miniature implantable osmotic pumps and accessories for experimental research in mice, rats, and other laboratory animals, as well as conducts research and development of pharmaceutical products in collaboration with third party pharmaceutical and biotechnology companies. Further, it designs, develops, and manufactures various biodegradable polymers based on lactide, glycolide, and caprolactone under the LACTEL brand for pharmaceutical and medical device clients for use as raw materials in their products. The company has collaboration agreements with Alpharma Ireland Limited; Nycomed Danmark, APS; Pain Therapeutics, Inc.; Endo Pharmaceuticals Inc; Voyager Pharmaceutical Corporation; ALZA Corporation; EpiCept Corporation; and NeuroSystec Corporation. DURECT Corporation was founded in 1998 and is based in Cupertino, California.

DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand.. Read More

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. Its lead product candidate includes HEPLISAVTM, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than.. Read More

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, manufacture, and license of orally administered controlled release drug delivery systems and products in the United States. It offers two daily allergy products, Lodrane 24 and Lodrane 24D. The company also.. Read More

Endo Pharmaceuticals Holdings Inc., a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The companys products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The companys generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited. The company was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.

Entropin, Inc. ceased its operations in May 2005. Prior to 2005, the company engaged in the research and development of pharmaceutical products, primarily including its proprietary compound ENT-103 for pain therapy. The company was founded in 1984 and is based in Bradenton, Florida.

Forest Laboratories, Inc. develops, manufactures, and sells branded and generic forms of ethical drug products. Its principal products include Lexapro to treat depression; Namenda to treat Alzheimer's disease; Bystolic, beta-blocker to treat hypertension; and Savella for the treatment of fibromyalgia. The company also provides Sudocrem, a topical preparation to treat diaper rash; Colomycin, an antibiotic to treat cystic fibrosis; Infacol, which is used to treat infant colic; and Exorex, which is to treat eczema and psoriasis. In addition, its products include Dutogliptin, a small molecule dipeptidyl-peptidase-4 inhibitor, which is in Phase III studies to treat Type II diabetes mellitus; F2695 that completed Phase II study and is a selective norepinephrine and serotonin reuptake inhibitor for the treatment of depression and other central nervous system disorders; and ceftaroline acetate, a injectable cephalosporin antibiotic that exhibits bactericidal activity against the strains of gram-positive bacteria. Further, the companys products comprise NXL104, an intravenous beta-lactamase inhibitor; Linaclotide for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation; Aclidinium, an inhaling therapy, which is in Phase III studies for chronic obstructive pulmonary disease; and Cariprazine, an atypical antipsychotic in Phase II(b) studies for the treatment of schizophrenia, bipolar mania, and other psychiatric conditions. Additionally, its products include Oglemilast, a phosphodiesterase-IV inhibitor in Phase II study to treat COPD and asthma; and Benicar, an angiotensin receptor blocker to treat hypertension. The company has collaboration and license agreements Phenomix Corporation, Pierre Fabre Medicament, Novexel, S.A., Laboratorios Almirall, S.A., Gedeon Richter Ltd., Glenmark Pharmaceuticals Ltd., and AstraZeneca plc. Forest Laboratories, Inc. was founded in 1956 and is based in New York, New York.

Gamma Pharmaceuticals, Inc. operates as a marketing and product formulation company. The company focuses on the formulation, marketing, and sale of vitamins and nutriceuticals, over the counter pharmaceutical products, and personal care products in the Greater China and the United States. Its product formulations are based on its proprietary Gel Delivery Technology and are marketed and sold as wellness products. The company offers a suite of gel product forms, including gummy gels, liquid gels, crystal gels, and gel strips. Its products include hand sanitizer lotion, supplement multivitamins, supplement calcium, supplement vitamin C, and adjunctive supplement immune boosters and energy boosters, as well as for improved cognition, reducing the side effects of chemotherapy, symptoms of type II diabetes and pre-diabetes, symptoms of menopause, and stress reduction. The company offers products under the BrilliantChoice, Savvy, Jugular Energy Products, and IceDrops. It also manufactures house brands for retail accounts. The company was formerly known as Sunburst Pharmaceuticals, Inc. and changed its name to Gamma Pharmaceuticals, Inc. in July 2006. Gamma Pharmaceuticals was founded in 1993 and is headquartered in Las Vegas, Nevada.

Gentium S.p.A., a biopharmaceutical company, engages in the research, development, and manufacture of drugs to treat and prevent various vascular diseases and conditions related to cancer and cancer treatments. It develops and manufactures defibrotide, DNA based drug derived from pig intestines, to treat and.. Read More

Geron Corporation, a biopharmaceutical company, develops therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. The company develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase.. Read More

The Company, through its subsidiaries, is engaged in a Cancer Diagnosis and Treatment Center, which is a joint operation of PET Scanner and Rotary Gamma Ray Stereotactic Neurosurgery System imaging center in the PRC.

Inspire Pharmaceuticals, Inc., a biopharmaceutical company, engages in researching, developing, and commercializing prescription pharmaceutical products for ophthalmic and pulmonary diseases. The company offers AzaSite, an azithromycin ophthalmic solution and topical anti-infective; Elestat, an epinastine HCl.. Read More

Isis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating.. Read More

ISTA Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, discovers, develops, and markets therapies for inflammation, ocular pain, glaucoma, allergy, and dry eye in the United States. The company offers Xibrom for the treatment of inflammation and pain following cataract surgery; Istalol for the treatment of glaucoma; and Vitrase for use as a spreading agent. Its developing products include Bepotastine ophthalmic solution for allergic conjunctivitis; T-Pred, a Phase III clinical trial product candidate for the treatment of steroid-responsive inflammatory ocular conditions; Ecabet Sodium, a Phase IIb clinical trial product, for the treatment of dry eye syndrome; and Bepotastine nasal for the treatment of allergic rhinitis. The companys products developing products also include a steroid product candidate to treat ocular inflammation; iganidipine to enhance ocular nerve blood flow; and a formulation of latanoprost for the treatment of glaucoma. It sells its products primarily to drug wholesalers, retailers, and distributors, including chain drug stores, hospitals, clinics, government agencies, and managed healthcare providers. ISTA Pharmaceuticals was formerly known as Advanced Corneal Systems, Inc. and changed its name to ISTA Pharmaceuticals, Inc. in March 2000. The company was founded in 1992 and is headquartered in Irvine, California.

Kendle International Inc., a clinical research organization, provides clinical development services on a contract basis to the biopharmaceutical industry worldwide. The companys clinical development services include clinical trial management, clinical data management, statistical analysis, medical writing, regulatory consulting and organizational meeting management, and publications services. It operates through two segments, Early Stage and Late Stage. The Early Stage segment focuses on its Phase I operations. The Late Stage segment comprises clinical development services related to Phase II through III clinical trials; late phase clinical development services related to Phase IIIB and IV clinical trials. It also provides regulatory expertise and consulting services at various stages of drug and device development; designs clinical programs and clinical trial protocols, reviews programs, and provides gap analysis; offers consulting services for nonclinical development for small molecules, biologicals, vaccines, and devices; assists in the U.S. Food and Drug Administration application process; and involves in collection, analysis, and reporting of drug safety data. In addition, this segment offers customized clinical data management with the ability to connect into and utilize a customers own data systems. Kendle International operates in North America, Europe, Asia/Pacific, Latin America, and Africa. The company was founded in 1981 and is based in Cincinnati, Ohio.

King Pharmaceuticals, Inc. research and develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products worldwide. The companys branded prescription pharmaceuticals include neuroscience products, such as Skelaxin, Avinza, and Sonata; hospital products, including Thrombin-JMI and Synercid; acute care products that comprise Bicillin and Intal; and legacy products consisting of Altace, Levoxyl, and Cytomel to general/family practitioners, internal medicine physicians, neurologists, pain specialists, surgeons, and hospitals. Its animal health business focuses on medicated feed additives (MFAs) and water-soluble therapeutics, which are anti-infective products primarily for poultry, cattle, and swine markets. The company also manufactures and markets pharmaceutical products that are delivered using an auto-injector to commercial and government markets. Its auto-injector products include EpiPen, an auto-injector filled with epinephrine for the treatment of anaphylaxis resulting from severe or allergic reactions to insect stings or bites, foods, drugs, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; the nerve agent antidotes, including AtroPen and ComboPen; and the Antidote Treatment Nerve Agent Auto-injector. King Pharmaceuticals also licenses rights to third-party pharmaceutical companies to manufacture and market adenosine-based products, Adenoscan and Adenocard. Adenoscan is a sterile, intravenous solution of adenosine administered intravenously as an adjunct to imaging agents used in cardiac stress testing of patients. Adenocard is a sterile solution of adenosine administered intravenously in emergency situations to convert certain irregular heart rhythms to normal sinus rhythms. It distributes its branded pharmaceutical products through wholesale pharmaceutical distributors and a sales force. King Pharmaceuticals was founded in 1993 and is headquartered in Bristol, Tennessee.

Lannett Company, Inc. develops, manufactures, markets, and distributes generic versions of pharmaceutical products in the United States. The company manufactures and/or sells various prescription products. Its product portfolio includes acetazolamide, baclofen, and bethanechol chloride tablets; amantadine gel capsules; butalbital, aspirin, and caffeine with codeine phosphate, danazol, and clindamycin HCl capsules; cocaine topical solution; and dicyclomine tablets and capsules. The companys products also comprise digoxin, dipyridamole, doxycycline, doxycycline hyclate, esterified estrogen and methyltestoterone, hydrochlorothiazide, hydromorphone HCl, and levothyroxine sodium tablets; morphine sulfate oral solutions; and OB-natal one gel capsules. In addition, its products consist of pilocarpine HCl, primidone, probenecid, terbutaline sulfate, and unithroid tablets; oxycodone HCl oral solution; rifampin and ursodiol capsules; and phentermine HCl tablets and capsules. Lannett Company markets its products under the brand names of Diamox, Symmetrel, Lioresal, Urecholine, Fiorinal, Cleocin, Danocrine, Bentyl, Lanoxin, Persantine, Adoxa, Periostat, Estratest, Hydrodiuril, Dilaudid, Levoxyl/ Synthroid, Roxanol, PrimaCare ONE, Roxicodone, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Actigall, and Fiorinal w/ Codeine #3. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania.

Lescarden Inc. engages in the research, testing, and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, and cancer applications. The company offers CATRIX Wound Dressing, a powder derived from bovine cartilage for the management of chronic lesions and.. Read More

MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development.. Read More

Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer in the United States and Australia. The company involves in the clinical development and commercialization of its phenoxodiol drug candidates for the.. Read More

Med Gen, Inc. manufactures and markets healthcare products, primarily to the market for alternative therapies. Its flagship product is SNORenz, a throat spray, which reduces or eliminates the sounds ordinarily associated with snoring. The company also provides other products, including Good Nights Sleep, a liquid.. Read More

The Medicines Company, a pharmaceutical company, provides medicines for the treatment of critical care patients worldwide. It markets Angiomax, an intravenous direct thrombin inhibitor for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty; and Cleviprex, a dihydropyridine calcium channel blocker, for the control of high blood pressure. The companys development products include cangrelor, an injectable antiplatelet agent that prevents platelet activation and aggregation in the clotting process; Oritavancin, a semi-synthetic lipoglycopeptide antibiotic for the treatment of gram-positive infections; and CU-2010 for the prevention of blood loss during surgery. Its customers include hospital management, physicians, hospital pharmacists, nurses, and other care staff. The Medicines Company sells its products through sales representatives and managers. The company has commercial supply agreement with Lonza Braine S.A. for the development and supply of the Angiomax bulk drug substance. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

MiddleBrook Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of anti-infective drug products in the United States. The company develops a proprietary delivery technology called PULSYS, which enables the pulsatile delivery, or delivery in rapid bursts, of drugs. Its.. Read More

Miravant Medical Technologies engages in the research and development of drugs and medical device products for use in photodynamic therapy. It also manufactures light producing and light delivery devices. The companys drugs when activated by light induce a photochemical reaction in the presence of oxygen that.. Read More

Naturade, Inc. engages in the development and marketing of branded natural products and nutritional supplements in the United States, Canada, and internationally. Its products include Naturade Total Soy, a line of nutritionally complete meal replacements for weight loss and cholesterol reduction; Naturade protein.. Read More

Neurochem, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics primarily for the treatment of neurological disorders. Its product candidates include eprodisate, which has completed Phase III clinical trial for the treatment of amyloid A amyloidosis. The company is.. Read More

NeurogesX, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing novel pain management therapies. The companys lead product candidate Qutenza, a dermal patch containing synthetic capsaicin, completed its phase III clinical trials to manage pain associated with peripheral.. Read More

Neuro-Hitech, Inc., a specialty pharmaceutical company, focuses on developing, marketing, and distributing branded and generic pharmaceutical products primarily for the cough and cold markets in the United States. Its branded pharmaceutical products include Maxiphen, Maxifed, Maxi-Tuss, Allfen, Promacet,.. Read More

NexMed, Inc., a pharmaceutical and medical technology company, engages in the development of topical pharmaceutical products based on its proprietary NexACT transdermal drug delivery technology. The NexACT transdermal drug delivery technology is designed to enhance the absorption of an active drug through the skin and enable concentrations of the active drug to penetrate the desired site of the skin or extremity. The companys products under development include NM100060, a topical nail solution for the treatment of onychomycosis; Vitaros, a topical alprostadil-based cream treatment for patients with erectile dysfunction; and Femprox, an alprostadil-based cream product for the treatment of female sexual arousal disorder. It also focuses on the development of topical treatments for psoriasis. The company has a licensing agreement with Novartis International Pharmaceutical Ltd. for the development, manufacture, and commercialization of NM100060. NexMed, Inc. was founded in 1987 and is based in East Windsor, New Jersey.

NovaBay Pharmaceuticals, Inc., a mid-stage biopharmaceutical company, focuses on developing product candidates for the treatment or prevention of a range of infections in hospital and non-hospital environments. Its proprietary Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are anti-infective molecules produced by white blood cells when defending the body against invading pathogens. These compounds could form a platform to create various products to address the needs in the treatment and prevention of bacterial and viral infections. The companys lead product candidate, NVC-422, is used for the treatment of eye, ear, and sinus infections, and for use in contact lens solutions, as well as to destroy bacteria in the bladder, and bacteria that have formed biofilm within the catheter. It also offers NVC-101, a proprietary solution of hypochlorous acid used as a wound cleanser and debriding agent. NovaBay Pharmaceuticals has a licensing and research collaboration agreement with Alcon Manufacturing Ltd. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions, as well as an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo, and other dermatological indications. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in August 2007. NovaBay Pharmaceuticals was incorporated in 2000 and is based in Emeryville, California.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulin franchise, including modern insulins, human insulins, insulin-related.. Read More

Opko Health, Inc., a specialty healthcare company, engages in the discovery, development, and commercialization of proprietary pharmaceuticals, drug delivery technologies, diagnostic systems, and instruments for the treatment, diagnosis, and management of ophthalmic disorders. The companys product candidates.. Read More

Orexigen Therapeutics, Inc., a biopharmaceutical company, focusing on the development of pharmaceutical product candidates for the treatment of obesity. The companys lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later.. Read More

Oxis International, Inc. focuses on the research, development, and marketing of nutraceutical products in the field of oxidative stress reduction. Its nutraceutical products include L-Ergothioneine (ERGO), an over-the-counter antioxidant offered as a dietary supplement. ERGO is naturally occurring, water soluble,.. Read More

Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of.. Read More

Pharmacyclics, Inc. operates as a clinical-stage biopharmaceutical company focusing on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. The companys products in clinical development includes HDAC Inhibitor for advanced solid tumors, recurrent lymphomas, and sarcoma; Factor VIIa Inhibitor for cancer therapy; B Cell Tyrosine Kinase Inhibitor for the treatment of B-Cell lymphomas, and autoimmune diseases and mast cell diseases; and MGd for primary brain tumor and childhood brain tumors. Its pre-clinical development products comprise B Cell Tyrosine Kinase Inhibitors for autoimmune disease and mast cell disease; and HDAC8 Inhibitors for the treatment of autoimmune and cancer. The company was founded in 1991 and is headquartered in Sunnyvale, California.

Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing novel drugs to treat viral infections. Its primary focus is on the development of nucleoside/tide analogs as oral therapeutics for the treatment of chronic hepatitis C virus (HCV) infection; and.. Read More

Pharmaxis, Ltd. engages in the research, development, and commercialization of human healthcare products for the treatment and management of chronic respiratory and immune diseases primarily in Australia. The companys products include Aridol, a proprietary dry powder formulation of mannitol, which is used for the diagnosis and management of asthma and chronic obstructive pulmonary diseases; and Bronchitol, which is under Phase III clinical trial for the treatment of chronic obstructive lung diseases, including cystic fibrosis, bronchiectasis, and chronic bronchitis. Its products in preclinical development stage includes PXS25, an inhibitor of the mannose 6 phosphate receptor and PXS4159, an inhibitor of semicarbazide sensitive amine oxidase/vascular adhesion protein-1. The company, formerly known as Pharmaxis Pty, Ltd., was founded in 1998 and is headquartered in Frenchs Forest, Australia.

Primarily engaged in the sale of medical equipment and the providing of consultation services in the pharmaceutical business.

POZEN, Inc. engages in the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. The company has development and commercialization alliances with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without.. Read More

Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs in Australia. The company offers PBT-2, a Phase IIa clinical trial product for the treatment of Alzheimers disease. Its product is designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The companys product is also applied for other therapies, including age-related cataracts, Huntington disease, Creutzfeldt-Jakob disease, Motor Neuron disease, age-related macular degeneration, cancers, Parkinsons disease, and other neurodegenerative diseases. Prana Biotechnology Limited was founded in 1997 and is based in Parkville, Australia.

Protalex, Inc., a development stage company, engages in the development of biopharmaceutical drugs for the treatment of autoimmune and inflammatory diseases in the United States. The company targets the autoimmune diseases rheumatoid arthritis and idiopathic thrombocytopenic purpura. Its lead compound, PRTX-100,.. Read More

Puramed Bioscience, Inc. engages in the development and marketing of non-prescription medicinal and healthcare products. Its principal products include LipiGesic M, which provides acute relief from migraine headaches; and LipiGesic PM that provides remedy for insomnia and other sleep disorders. The companys.. Read More

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development.. Read More

Reliv International, Inc. engages in the development, manufacture, and marketing of nutritional supplements. Its basic nutrition supplements include Reliv Classic and Reliv NOW, which offer a balanced blend of vitamins, minerals, proteins, and herbs; NOW for Kids, which provide a balanced nutritional supplement for a childs diet; and Reliv Delight, a powdered nutritional supplement sold as a milk replacement. The companys specific wellness supplements comprise ReversAge, a youth-promoting nutritional supplement designed to slow down the effects of the aging process; SoySentials designed for use by women; CardioSentials, which promotes heart health; Arthaffect, which supports healthy joint function; FibRestore that contains fiber, vitamins, minerals, and herbs; and GlucAffect, which assists in healthy blood sugar management and support weight loss. Reliv Internationals weight management supplements include Reliv Ultrim-Plus, a meal replacement; Cellebrate to suppress appetite, curb the storage of body fat, and facilitate the bodys fat burning process; and Slimplicity meal replacement and accelerator capsules. The companys sports nutrition supplements comprise Innergize!, a sports supplement containing vitamins and minerals for performance enhancement, and ProVantage designed to increase muscle recovery, muscle mass, and function; reduce fatigue; and burn excess body fat for extra energy. It also offers ReversAge skin care product line, including balanced cleansing gel, body renewal lotion, smooth and lift serum, daily skin defense, eye renewal cream, nightly skin restore, and rich cleansing bar. Reliv International, Inc. markets its products through a network of independent distributors in the United States, Australia, Austria, Brunei, Canada, Germany, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, Singapore, the United Kingdom, and Indonesia. The company was founded in 1984 and is headquartered in Chesterfield, Missouri.

Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of travelers diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry. Santarus was founded in 1996 and is based in San Diego, California.

SciClone Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cancer and infectious diseases in China and internationally. It provides ZADAXIN for the treatment of hepatitis B and hepatitis C, and certain cancers, as well as for use as a vaccine adjuvant. The companys products under development includes ZADAXIN, a thymalfasin, which is in Phase III clinical trials for the treatment of stage IV melanoma; RP101, which is in Phase II clinical trials for the treatment of pancreatic cancer; and SCV-07, which is in Phase II clinical trials for the treatment of hepatitis C virus and oral mucositis. It also holds Chinese marketing rights from Biocompatibles International plc. for DC Bead, a product for the treatment of liver cancer or hepatocellular carcinoma. The company was founded in 1989 and is headquartered in Foster City, California.

Shire plc, together with subsidiaries, engages in the research, development, manufacture, sale, and distribution of pharmaceutical products. It operates in two segments: Specialty Pharmaceuticals and Human Genetic Therapies. The Specialty Pharmaceuticals segment offers products for the treatment of attention.. Read More

SIGA Technologies, Inc., a biotechnology company, engages in the discovery, development, and commercialization of anti-infectives, antibiotics, and vaccines for the prevention and treatment of serious infectious diseases. The company focus on products for use in defense against biological warfare agents, such as smallpox, arenaviruses (hemorrhagic fevers), and other category A viral agents. Its lead product, ST-246, is an orally administered anti-viral drug that targets orthopox viruses. The companys product candidates also include ST-294 and ST-193, which demonstrates antiviral activity in cell culture assays against arenavirus pathogens; and ST-669, a broad spectrum antiviral candidate, for various viruses in the Poxviridae, Filoviridae, Bunyaviridae, Arenaviridae, Flaviviridae, Togaviridae, Retroviridae, and Picornaviridae families. In addition, it also has four drug series in the pre-clinical development stage, including ST-610 and ST-148 for dengue virus of the genus Flavivirus. The company has license agreements, collaborative research arrangements, and contracts with National Institutes of Health and the United States Air Force. SIGA Technologies was founded in 1995 and is headquartered in New York, New York.

Simcere Pharmaceutical Group engages in the research, development, manufacture, distribution, and marketing of branded generic pharmaceutical products in the Peoples Republic of China. Its principal products include prescription edaravone injection for the treatment of strokes under the Bicun brand; amoxicillin.. Read More

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. The company has completed four Phase III clinical trials for its lead product.. Read More

Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system.. Read More

SuperGen, Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of therapies to treat patients with cancer. The company licensed its new drug application approved product, Dacogen for the treatment of patients with myelodysplastic syndromes. It primarily focuses on.. Read More

Synergy Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead drug candidates include SP-304, a guanylyl cyclase C (GC-C) receptor agonist, which has completed Phase I clinical trial to.. Read More

Tapestry Pharmaceuticals, Inc., together with its subsidiaries, focuses on the development of proprietary therapies for the treatment of cancer. It also engages in evaluating new therapeutic agents and/or related technologies that involve the examination of individual molecules, classes of compounds, or platform.. Read More

Taro Pharmaceutical Industries, Ltd. engages in the development, manufacture, and marketing of prescription and over-the-counter pharmaceutical products, as well as active pharmaceutical ingredients primarily in the United States, Canada, and Israel. Its primary areas of focus include topical creams and.. Read More

Telik, Inc., a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer and inflammatory diseases. The companys advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA, a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the discovery of small molecule drug candidates. The company was founded in 1988 and is based in Palo Alto, California.

Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. Its research and development efforts focus on therapies for the central nervous system (with emphasis on multiple sclerosis), autoimmune diseases, and oncology. The companys principal products include Copaxone for multiple sclerosis; and Azilect for Parkinsons disease. Teva Pharmaceutical also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; and Cyclohaler, a single dose dry powder device. The companys branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm, and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it offers APIs for respiratory products, dermatological hormones, anti-inflammatories, oncolytics, immunosuppressants, and muscle relaxants, as well as custom-manufactured APIs for various proprietary drug manufacturers. Teva Pharmaceutical added women's health portfolio to its specialty pharmaceutical platform through the acquisition of Barr Pharmaceuticals Inc. The company also holds a biotechnology platform focused on the development of peptide and protein-based medicines through the ownership of CoGenesys, Inc., a biopharmaceutical company. It has a collaboration agreement with Optimata Ltd. to develop solid tumor cancer drugs; a strategic alliance with Kowa Company, Ltd. to establish a generic pharmaceutical company in Japan; and a strategic partnership with the Lonza Group in a joint venture to develop, manufacture, and market a portfolio of biogenerics. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.

Tianyin Pharmaceutical Co., Inc. engages in the development, manufacture, marketing, and sale of modernized traditional Chinese medicines and other pharmaceuticals in the Peoples Republic of China. The companys products are intended to address various medical needs in the therapeutic areas spanning internal.. Read More

A development stage company engaged in developing and testing organ transplantation therapies based on an approach employing organ-specific precursor tissues.

Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including.. Read More

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of therapeutic products for patients with chronic and life-threatening cardiovascular and infectious diseases, and cancer in the United States and Internationally. The companys products include Remodulin (treprostinil sodium) for the treatment of pulmonary arterial hypertension; and CardioPAL SAVI and Decipher Cardiac Monitors for the treatment of cardiac arrhythmias and ischemic heart disease. Its NDA filed products include Inhaled Treprostinil for pulmonary arterial hypertension and Oral Tadalafil for pulmonary hypertension. The companys Phase III products comprise of Oral Treprostinil for pulmonary arterial hypertension; and Phase II products include Beraprost-MR for pulmonary arterial hypertension, 3F8 MAb for neuroblastoma, Oral Treprostinil for Peripheral vascular disease, and CardioPAL SAVI Wireless Cardiac Event Monitors for Cardiac arrhythmias and ischemic heart disease. Its Phase I products include Inhaled Treprostinil for pulmonary arterial hypertension associated with Idiopathic pulmonary fibrosis, Inhaled Treprostinil with AERx Essence for Pulmonary hypertension, 8H9 MAb for Metastatic brain cancer, and Celgosivir for Hepatitis C. The companys pre-clinical products comprise Miglustat for Hepatitis C and Glycobiology Antiviral Agents for Hepatitis C and other infectious diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.

Valeant Pharmaceuticals International, a specialty pharmaceutical company, engages in the development, manufacture, and marketing of a range of pharmaceutical products. It primarily offers specialty pharmaceutical and over-the-counter (OTC) products in the areas of dermatology and neurology therapeutic classes. The companys products include Efudex/Efudix for the treatment of multiple actinic or solar keratoses and superficial basal cell carcinoma; Diastat/Diastat AcuDial, which are gel formulations of diazepam; Cesamet, a synthetic cannabinoid used for the management of severe nausea and vomiting; Bedoyecta, a brand of vitamin B complex; Bisocard to treat hypertension and angina pectoris; and Kinerase, a range of OTC and prescription cosmetic products. It also offers Mestinon, an orally active cholinesterase inhibitor used in the treatment of myasthenia gravis; M.V.I., a hospital dietary supplement used in treating trauma and burns; Migranal, a nasal spray formulation for the treatment of acute migraine headaches; Nyal to treat cough, cold, flu, sinus, and hayfever symptoms; and Virazole for the treatment of hospitalized infants and young children with lower respiratory tract infections. As of December 31, 2008, its product portfolio comprised approximately 389 products, with approximately 982 stock keeping units. The company markets its pharmaceutical products to physicians, hospitals, pharmacies, and wholesalers through its sales force, as well as through wholesalers in the United States, Mexico, Poland, and Canada. It has a collaboration agreement with Glaxo Group Limited to develop and commercialize retigabine, a neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory partial onset seizures. Valeant Pharmaceuticals was founded in 1960 and is headquartered in Aliso Viejo, California.

Vaso Active Pharmaceuticals, Inc. focuses on the commercialization, marketing, and sale of over-the-counter (OTC) pharmaceutical products that incorporate a proprietary PENtoCORE technology. It also owns the OTC worldwide license to use and practice vaso active lipid encapsulated technology, a patchless, lipid-based delivery system. The companys products include Osteon, an OTC external analgesic, to provide temporary relief from the muscular skeletal pain associated with arthritis; A-R Extreme, an OTC external analgesic, to provide temporary relief from the muscle and joint pain associated with athletic activity; and Termin8, an OTC antifungal lotion to treat athlete's foot. It also develops acne treatment, analgesic utilizing ibuprofen, first aid treatments, hand and body lotions, psoriasis treatment, and toenail fungus treatment products. Vaso Active Pharmaceuticals distributes its products to chain drug and grocery stores. The company was founded in 2001 and is based in Danvers, Massachusetts. Vaso Active Pharmaceuticals, Inc. is a subsidiary of BioChemics, Inc.

A biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax and smallpox.

Vertex Pharmaceuticals Incorporated engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Its product pipeline includes Telaprevir, a Phase III clinical trial product for the treatment of hepatitis C virus (HCV) infection; VX-813, a.. Read More

Viral Genetics, Inc., a development stage company, engages in the research and development of protein-based therapeutic and diagnostic products in the United States. The company develops its products based on thymus nuclear protein compound, a processed extract of mammalian thymus tissue. Its products are used in.. Read More

Vital Living, Inc. engages in the development and marketing of nutritional fruit and vegetable supplements, protein supplements, and nutraceuticals products. The companys products include GreensFIRST, which supplies natural vitamins, minerals, plant enzymes, antioxidants, phytonutrients, and symbiotic intestinal.. Read More

Warner Chilcott Limited, a specialty pharmaceutical company, engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in womens healthcare and dermatology segments primarily in the United States. The company offers various women healthcare products, including LOESTRIN 24 FE and FEMCON FE as oral contraceptives; FEMHRT 1/5 and .5/2.5 for oral treatment of moderate to severe vasomotor symptoms and urogenital symptoms associated with menopause; and ESTRACE cream to treat vaginal and vulvar atrophy. It also offers various dermatology products, such as TACLONEX and DOVONEX for the topical treatment of psoriasis; and DORYX, an oral adjunctive therapy for severe acne. In addition, its products under development include WC3016 and WC3026, the Phase III clinical trial completed products for low-dose oral contraceptive; WC2055, a Phase II clinical trials completed product for the treatment of acne; WC3018, a Phase II clinical trials product for the treatment of acne and other inflammatory skin conditions; LEO 80-185 for psoriasis of the scalp; and LEO 80-190, a Phase III clinical trial product for the treatment of psoriasis. Further, the companys products under development comprise TD1414, a Phase II clinical trial product for skin infections; WC3027 for the treatment of inflammatory skin conditions; WC3035 for the treatment of acne and rosacea; and WC3036 and WC3043 for the treatment of erectile dysfunction. Warner Chilcotts principal customers include wholesale pharmaceutical distributors, and retail drug and grocery store chains. It has license and supply agreement with LEO Pharma A/S. The company was founded in 1968 and is headquartered in Rockaway, New Jersey.

YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide. Its approved product Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth.. Read More